Safety Study of Cenderitide in Chronic Stable Heart Failure With Moderate Renal Impairment
Status:
Completed
Trial end date:
2016-03-31
Target enrollment:
Participant gender:
Summary
CNDP-578-02 is a randomized, double-blind, placebo-controlled, dose-escalation, crossover
design trial. Eight evaluable subjects (n=8) with chronic stable heart failure and moderate
renal impairment will be randomized (1:1) to receive cenderitide or placebo. Enrolled
subjects will begin with Infusion Period A where they will receive up to 7 days of
continuous, subcutaneous, dose-escalating infusions of cenderitide or placebo via the Insulet
Drug Delivery System. Enrolled subjects will then cross over into Infusion Period B where
they will receive up to 7 days of continuous, subcutaneous, dose-escalating infusions of
cenderitide or placebo.